Variables | Â | All patients (n = 447) | SII > 395 (n = 280) | SII < 395 (n = 167) | p value |
---|---|---|---|---|---|
Age, years | Median | 67 | 67 | 67 | 0.215 |
Range | 29–89 | 29–89 | 39–89 | ||
Sex | Male | 289 | 176 (62.9%) | 113 (67.7%) | 0.302 |
Female | 158 | 104 (37.1%) | 54 (32.3%) | ||
BMI, kg/m2 | Median | 22.2 | 21.9 | 23.1 | 0.021* |
Range | 14.4–34.2 | 14.4–34.2 | 15.6–30.6 | ||
PS | 1 | 233 | 146 (52.1%) | 87 (52.1%) | 0.992 |
> 2 | 214 | 134 (47.9%) | 80 (47.9%) | ||
Hypertension | Presence | 114 | 77 (27.5%) | 37 (22.2%) | 0.210 |
Absence | 333 | 203 (72.5%) | 130 (77.8%) | ||
Diabetes mellitus | Presence | 64 | 35 (12.5%) | 29 (17.4%) | 0.155 |
Absence | 383 | 245 (87.5%) | 138 (82.6%) | ||
Heart disease | Presence | 50 | 30 (10.7%) | 20 (12.0%) | 0.682 |
Absence | 397 | 250 (89.3%) | 147 (88.0%) | ||
Chronic renal failure | Presence | 10 | 6 (2.1%) | 4 (2.4%) | 0.862 |
Absence | 437 | 274 (97.9%) | 163 (97.6%) | ||
Tumor location | Upper | 145 | 96 (34.3%) | 49 (29.3%) | 0.278 |
Middle/lower | 302 | 184 (65.7%) | 118 (70.7%) | ||
CEA, ng/ml | < 5 | 390 | 240 (85.7%) | 150 (89.8%) | 0.202 |
≥ 5 | 57 | 40 (14.3%) | 17 (10.2%) | ||
CA19-9, U/ml | < 37 | 422 | 261 (93.2%) | 161 (96.4%) | 0.143 |
≥ 37 | 25 | 19 (6.8%) | 6 (3.6%) | ||
Albumin, g/dl | < 3.5 | 19 | 17 (6.1%) | 2 (1.2%) | 0.014* |
≥ 3.5 | 428 | 263 (93.9%) | 165 (98.8%) | ||
CRP, mg/dl | < 0.5 | 397 | 245 (87.5%) | 152 (91.0%) | 0.254 |
≥ 0.5 | 50 | 35 (12.5%) | 15 (9.0%) | ||
Neutrophil count, cell/mm3 | Median | 3690 | 4145 | 3060 | < 0.001* |
Range | 1250–15,850 | 1250–15,850 | 1420–7630 | ||
Lymphocyte count, cell/mm3 | Median | 1780 | 1630 | 2050 | < 0.001* |
Range | 570–4770 | 570–4770 | 1050–4640 | ||
Monocyte count, cell/mm3 | Median | 330 | 340 | 310 | 0.008* |
Range | 50–1400 | 50–1400 | 100–750 | ||
Platelet count, cell/mm3 × 104 | Median | 225 | 245 | 190 | < 0.001* |
Range | 87–570 | 570–117 | 87–314 | ||
pT | pT1–3 | 399 | 248 (88.6%) | 151 (90.4%) | 0.539 |
pT4 | 48 | 32 (11.4%) | 16 (9.6%) | ||
pN | pN0 | 323 | 189 (67.5%) | 134 (80.2%) | 0.003* |
pN+ | 124 | 91 (32.5%) | 33 (19.8%) | ||
Lymphatic invasion | Presence | 169 | 120 (42.9%) | 49 (29.3%) | 0.004* |
Absence | 278 | 160 (57.1%) | 118 (70.6%) | ||
Venous invasion | Presence | 138 | 95 (33.9%) | 43 (25.7%) | 0.068 |
Absence | 309 | 185 (66.1%) | 124 (74.3%) | ||
Tumor differentiation | Differentiated | 231 | 133 (47.5%) | 98 (58.7%) | 0.022* |
Undifferentiated | 216 | 147 (52.5%) | 69 (41.3%) |